Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum

Autor(es):Mostrar menos -

Cecchini, Mario Amore ^[1] ; Yassuda, Monica Sanches ^{[2, 3]} ; Squarzoni, Paula ^[4] ; Coutinho, Artur Martins ^{[4, 5]} ; Faria, Daniele de Paula ^{[6, 7]} ; de Souza Duran, Fabio Luiz ^[4] ; da Costa, Naomi Antunes ^[4] ; de Gobbi Porto, Fabio Henrique ^[4] ; Nitrini, Ricardo ^[3] ; Forlenza, Orestes Vicente ^[7] ; Dozzi Brucki, Sonia Maria ^[3] ; Buchpiguel, Carlos Alberto ^[5] ; Parra, Mario A. ^[8] ; Busatto, Geraldo F. ^{[4, 6]}

Afiliação do(s) autor(es)

^[1] Univ Edinburgh, Human Cognit Neurosci Psychol, Edinburgh, Midlothian - Scotland

^[2] Univ Sao Paulo, Sch Arts Sci & Humanities, Gerontol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med, Neurol, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Lab Psychiat Neuroimaging LIM 21, Hosp Clin, Dept & Inst Psiquiatria, Sch Med, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Lab Nucl Med LIM43, Ctr Med Nucl, Dept Radiol & Oncol, Sch Med, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Nucleo Apoio Pesquisa Neurociencia Aplicada NAPNA, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Sch Med, Dept Psychiat, Lab Neurosci LIM 27, Sao Paulo - Brazil

^[8] Univ Strathclyde, Sch Psychol Sci & Hlth, Glasgow, Lanark - Scotland

• Tipo de documento: Artigo Científico
• Fonte: BRAIN AND COGNITION; v. 152, AUG 2021.
• Citações Web of Science: 0

Resumo

The short-term memory binding (STMB) test involves the ability to hold in memory the integration between surface features, such as shapes and colours. The STMB test has been used to detect Alzheimer's disease (AD) at different stages, from preclinical to dementia, showing promising results. The objective of the present study was to verify whether the STMB test could differentiate patients with distinct biomarker profiles in the AD continuum. The sample comprised 18 cognitively unimpaired (CU) participants, 30 mild cognitive impairment (MCI) and 23 AD patients. All participants underwent positron emission tomography (PET) with Pittsburgh compound B labelled with carbon-11 ({[}C-11]PIB) assessing amyloid beta (A beta) aggregation (A) and 18fluorine-fluorodeoxyglucose ({[}F-18]FDG)-PET assessing neurodegeneration (N) (A -N-{[}n = 35]); A+N-{[}n = 11]; A+ N+ {[}n = 19]). Participants who were negative and positive for amyloid deposition were compared in the absence (A-N vs. A+N-) of neurodegeneration. When compared with the RAVLT and SKT memory tests, the STMB was the only cognitive task that differentiated these groups, predicting the group outcome in logistic regression analyses. The STMB test showed to be sensitive to the signs of AD pathology and may represent a cognitive marker within the AD continuum. (AU)

• Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
• Beneficiário: Wagner Farid Gattaz
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/50197-3 - A novel cognitive biomarker to screen for dementia across cultures and countries
• Beneficiário: Monica Sanches Yassuda
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 12/50329-6 - Neurociência translacional da doença de Alzheimer: estudos pré-clínicos e clínicos do peptídeo b-amiloide e outros biomarcadores
• Beneficiário: Geraldo Busatto Filho
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/07967-2 - Marcadores neurocognitivos para o diagnóstico precoce e diferencial para a Doença de Alzheimer e a demência frontotemporal: variante comportamental
• Beneficiário: Monica Sanches Yassuda
• Modalidade de apoio: Auxílio à Pesquisa - Regular